CD8A and non-small cell lung carcinoma: In a recent study, the percentage of CD28−, CD57+, and KLRG1+ cells among CD8+ T-cells (senescent immune phenotype, SIP) was assessed by flow cytometry in blood from patients with advanced NSCLC [48].